The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Interesting to read that LFD testing for NHS staff appears to be a short term measure until LAMP pathology hubs are established for this purpose (Q13 on the NHS document). LFD will then be deployed for general public screening I expect, based upon the PM briefing earlier today.
Good time for us to be developing a LAMP test then.
The £406m amount might be a limit of liability with the contract being based on a call-off arrangement whereby the customer will receive goods upon request, with a limit of £406m on total aggregate value. The £150m value for the contract quoted in the RNS probably relates to the value that the customer and supplier (primerdesign) anticipate within the contract for phase 1, and an additional £100m estimated most likely value if phase 2 option is taken. As the required numbers of tests was and remains very much a variable, the additional amount within the £406m lol enables the customer to receive more than was anticipated without the need to hastily arrange a new contract or an extension to the existing. Its quite a common arrangement.
The RNS says exactly what the LFT is for. It’s not at all about detecting an infection, it’s to determine whether the recipient of the test has had the virus (or a vacccine). The same as the UK-RTC test that ODX have been involved in.
Don’t disagree but the article is still incorrect. I don’t see that there is any need to guild the lily where this share is concerned. We already know that the strength of the brand, the sales to date and the future prospects speak for themselves. I’m not a fan of Twitter rampers or the insider fanzine because there can be a tendency for some presentation of opinion and assumption as fact and that can act as a red flag to investors.
The article refers to the ‘original deal’ for 1000 machines. As far as I understand that is incorrect. The original deal is 300 units and the potential for a further 700 units exists at the discretion of the DHSC. At this time we have not yet heard whether the option has been taken so can only assume that it hasn’t, yet, because when it is then it will have to be announced by the company due to the potential contract value?
There are antibody LFTs with sensitivity and specificity in those ranges already I believe from the government sponsored UK-RTC, so ours would have to be the same or similar in order to be competitive. I thought that we’d already RNS’s expected high accuracy values?
I’m not sure that Primerdesign tweets are at all related to or reflective of primerdesign commercial activity, more generally just industry and pandemic related commentary. As an example, primerdesign tweeted and commented on the same ITV good news story that had been posted on this board, about a daughter’s first visit to her mother in a care home for several weeks/ months, and that visit had been enabled by the daughter taking an Innova LFT test.
The same link was posted earlier. The daughter took a lateral flow test which then enabled her to visit her mother. No mention of NCYT and not the right type of test for it to be us either. Our trial was around the London area as someone mentioned earlier. Went very well by all accounts, so hopefully more to come on that in due course.
Fortunately we have only had once instance where a test has been required in our household. The PCR test appointment was within 2 hours of going online to book one and the negative result came back around 24 hours later. Couldn’t fault the process, especially in an area where rates and demand are both high, but we could carry on as normal within a day. Looks like you’ve been unlucky 9inchNail.
24hr operation would need 6 persons even if only 1 were required at any one time. I’d expect 3 shifts per day of ~8.5hrs each including handover with a pattern perhaps of 4 on, 3 off, 3 on, 4 off. That would give you the 7x24 availability to process 2000-2400 tests per day.